Aspen Confirms ‘Material’ Offers For API Unit Remain Under Consideration
Chemicals And Biochem Segments Saw Increased Sales In FY21; Higher Costs Bit
Aspen Pharmacare is continuing to ponder offloading another part of its operations, with bids under consideration for its significant API business units. The company only recently sold a basket of products in South Africa to Acino.
You may also be interested in...
South African’s Aspen Pharmacare has published first-half financials results that match a recent trading update, following a major reshaping. The new-look firm says it has “spent a long time building and a long time justifying building.”
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.